Evotec expects USD 100 million upfront from Gilead’s Tubulis acquisition

Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILD

0.00
  • Gilead agreed to buy antibody-drug conjugate developer Tubulis, triggering proceeds for Evotec from its equity stake.
  • Evotec expects about USD 100 million in upfront consideration at closing, slated for Q2 2026.
  • Contingent consideration could add up to about USD 58 million, subject to milestone achievements.
  • Evotec holds a 3.14% stake in Tubulis through Evotec Ventures.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evotec SE published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2304292_en), on April 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.